近日，成都先导药物开发股份有限公司的全资子公司Vernalis (R D) Ltd（以下称“Vernalis”）与Hox Therapeutics Ltd（以下称“Hox”）宣布达成合作，将针对未公开肿瘤靶点开发抑制剂。Hox是一家专注于开发高度靶向性癌症疗法的私营生物技术公司。
根据协议条款，Vernalis将利用其先进的蛋白科学专长和Hit ID平台生产靶蛋白，并对目标靶点的小分子抑制剂进行识别和表征，相关研究工作将由Hox支付费用。具体财务条款未披露。
Vernalis研发总监James Murray表示：
“Vernalis在临床阶段候选物发现方面拥有丰富的创新和成功经验，此次合作正是建立在这一基础之上。我们期待与Hox团队紧密合作，携手达成目标。”
Hox Therapeutics首席执行官Nicholas Adams表示：
“Vernalis在开发针对我们感兴趣的蛋白靶点的抑制剂方面拥有深厚的专业积淀。我们很高兴与Vernalis达成合作。”
关于Hox Therapeutics Ltd Hox Therapeutics是一家临床前阶段的生物技术公司，专注于发现和开发高度靶向性的癌症治疗创新药物。
关于Vernalis Vernalis是国际领先的专注于基于分子片段和三维结构信息的药物设计技术（FBDD/SBDD）公司，拥有将新药从发现阶段推进到临床阶段的丰富经验。Vernalis总部位于英国剑桥，通过全球合作，我们已经开发了多个针对肿瘤、神经退行性疾病、抗感染和炎症等靶点的先导化合物和临床阶段候选物。Vernalis是成都先导药物开发股份有限公司（688222.SH）的全资子公司。
了解更多信息，请访问：www.vernalis.com
Hox Therapeutics and Vernalis announce a drug discovery collaboration in oncology
Hox Therapeutics Ltd (“Hox”) a private biotechnology company developing highly targeted cancer therapies and Vernalis (R D) Ltd (“Vernalis”), a fully owned subsidiary of HitGen Inc., are pleased to announce a collaboration to identify inhibitors against an undisclosed oncology target.
Under the terms of the agreement, Vernalis will use its state-of-the-art protein science and Hit ID platforms to produce the target protein, and to identify and characterise small molecule inhibitors of the target. The research at Vernalis will be funded by Hox. Financial terms have not been disclosed.
James Murray, Research Director of Vernalis, said,“This partnership is built on Vernalis’s strong record for innovation in drug discovery to generate clinical candidates. We look forward to working closely with Hox to successfully achieve the goals of this collaboration”.
Nicholas Adams, CEO of Hox Therapeutics, said,“We are delighted to be working with Vernalis on this project. They have proven expertise in being able to identify inhibitors against the protein target that we’re interested in”.
About Hox Therapeutics Ltd
Hox Therapeutics is a preclinical-stage biotechnology company focused on the discovery and development of innovative, highly targeted medicines for the treatment of cancer.
For more information, please visit www.hoxtherapeutics.com
About VernalisVernalis is a world leader in fragment and structure-based drug discovery with a record of progressing targets from concept to clinic. Based in Cambridge, UK, we have generated development candidates across oncology, neurodegeneration, anti-infectives and inflammation, through global collaborations. Vernalis is a wholly owned subsidiary of HitGen Inc (688222.SH).
For more information about Vernalis, please visit www.vernalis.com